LIXTE Biotechnology (LIXT) engaged IBN to assist with its corporate communications strategy. As part of the client-partner relationship, IBN will leverage its investor-focused distribution network, which includes over 5,000 key syndication outlets, various newsletters, social media channels, and wire services via InvestorWire, along with blogs and other outreach tools, to generate greater awareness for LIXTE Biotechnology.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LIXT:
- LIXTE Biotechnology Holdings (NASDAQ: LIXT) Expands Ovarian Cancer Trial With MD Anderson and GSK
- Lixte Simplifies Capital Structure via Share Exchange Deal
- Lixte Expands LB-100 Ovarian Cancer Trial Collaboration
- Lixte Biotechnology expands collaboration to expand trial with LB-100
- Lixte Biotechnology Announces New Registered Direct Offering